Ovarian cancer: symptoms, CA-125 and how it is diagnosed

No screening test works for ovarian cancer, so a pattern of new, frequent symptoms is what catches it. CA-125 is the follow-up test, not the screen, and a normal result cannot rule cancer out.

Reviewed by LifeFrom’s medical AIPublished November 20, 2026 · 13 min
Ask AI about this pageChatGPTClaudePerplexity
The distinctions
  1. 01
    The symptoms find it, CA-125 follows up

    No blood test or scan screens for ovarian cancer: yearly CA-125 and ultrasound did not lower deaths in two large trials 39. What catches it earlier is a pattern of bloating, pelvic pain, early fullness or urinary urgency that is new and happens more than 12 times a month 4. CA-125 is the follow-up test for that pattern; a raised result leads to an ultrasound, and a normal one does not clear persistent symptoms.

No screening test lowers ovarian cancer deaths, so most cases come to light through a symptom pattern: new bloating, pelvic or belly pain, early fullness or needing to pee more, happening more than 12 times a month 4. That pattern leads to a CA-125 blood test and a pelvic ultrasound. About 21,010 US women will be diagnosed in 2026 and an estimated 12,450 will die of the disease 1. Five-year relative survival is 91.9% when the cancer is still confined to the ovary or tube, against 31.5% once it has spread far, and most cancers are found at that later stage 1.

54%of ovarian cancers are found after distant spreadOnly 22% are found while still localized. NCI SEER Cancer Stat Facts, 2026 1

What ovarian cancer is, and why the most common type often starts in the fallopian tube

Ovarian cancer is a group of cancers that start in the ovaries, the fallopian tubes or the peritoneum, the thin lining of the belly. Doctors treat all three as one disease because they behave alike and get the same treatment. It is uncommon: about 1 in 91 US women will be diagnosed in her lifetime, and the median age at diagnosis is 63 1. It is one of the deadliest gynecologic cancers because most cases are found late, and overall five-year relative survival is 52% 1.

About 9 in 10 ovarian cancers are epithelial, meaning they grow from the cells that cover these surfaces; doctors call these carcinomas, cancers of lining cells. The rest grow from egg cells (germ cell tumors), which mostly affect girls and younger women, or from the hormone-making tissue of the ovary (sex cord-stromal tumors). High-grade serous carcinoma, the most common and most deadly type, appears in many cases to begin at the frilled far end of the fallopian tube and reach the ovary later. ACOG, the American College of Obstetricians and Gynecologists, uses that finding to support removing the tubes during other pelvic surgery, a step called opportunistic salpingectomy 13.

Why most ovarian cancer is found late

1
A small cancer starts in the tube
The earliest change in many high-grade serous cancers sits at the open end of the fallopian tube, too small for any scan to see.
2
Cells shed into the belly
The tube opens straight into the belly, so cancer cells can drop onto the ovary and the peritoneum with no wall to cross.
3
Spread happens without a lump
The cells seed the belly lining as many small deposits, and fluid (ascites) starts to collect.
4
Symptoms arrive with the fluid
Bloating, fullness and pressure on the bladder often appear once the belly lining is involved.
Simplified sequence for high-grade serous cancer, the most common type. Stage figure from NCI SEER 1.
TypeWho it tends to affectRough shareBlood marker that tends to rise
High-grade serousMostly women over 50; most BRCA-linked cancersAbout 7 in 10 epithelial cancersCA-125
Endometrioid and clear cellWomen in their 40s and 50s; linked to endometriosisAbout 1 in 5 togetherCA-125, sometimes only mildly
MucinousWide age range; linked to smokingUnder 1 in 20Often normal CA-125; CEA and CA 19-9 instead
Low-grade serous and borderline tumorsYounger women; slow-growingSmall shareCA-125, often modest
Germ cell tumorsGirls and women under 30A few percent of ovarian cancersAFP, beta-hCG, LDH
Sex cord-stromal (granulosa cell)Any age, often around menopauseA few percentInhibin, AMH

Early signs of ovarian cancer and the 12-times-a-month rule

Four symptoms come up again and again in women later diagnosed with ovarian cancer: bloating or a belly that keeps getting bigger, pain in the pelvis or lower belly, feeling full quickly or losing your appetite, and needing to pee more often or more urgently. Each one is common and usually harmless. NICE, the guideline body for England, says the pattern is what makes these symptoms a reason for tests: persistent or frequent, particularly more than 12 times a month, especially in women 50 and over 4.

SymptomHow it tends to show up in ovarian cancerCommon harmless causeWorth getting checked when
Bloating or a growing bellyStays most of the day, does not settle overnight, clothes get tighter at the waistGas, constipation, IBS, the days before a periodIt is new and happens more than 12 days a month
Pelvic or belly painA dull, steady ache low in the belly or backPeriod pain, ovulation, constipation, a simple cystIt is new, most days, and not tied to your cycle
Feeling full fast or losing appetiteFull after a few bites; eating less without tryingIndigestion, reflux, stressIt lasts weeks, or comes with unexplained weight loss
Needing to pee more often or urgentlyPressure on the bladder, urgency without burningUrinary tract infection, overactive bladder, caffeineUrine tests are clear and it keeps going

Other signs include tiredness (fatigue), back pain, a change in bowel habit, weight loss you did not try for, and bleeding after menopause. In the study that built the original symptom index, Goff and colleagues found the four core symptoms, present more than 12 times a month for less than a year, in about 57% of women with early-stage cancer and 80% with advanced cancer 6. The symptom rule is a reason to get checked, not a reassurance: a woman without these symptoms can still have ovarian cancer.

Who is at higher risk, and what lowers it

Most women diagnosed with ovarian cancer have no known risk factor apart from age. The biggest single factor is an inherited variant (a gene change passed down in families) in BRCA1 or BRCA2 5. Lynch syndrome, the inherited condition best known for colon cancer, also raises the risk, as do variants in RAD51C, RAD51D and BRIP1.

Raises riskLowers risk
BRCA1 variant: about 44% by age 80 5Combined birth control pill: about 20% lower risk for every 5 years of use, with protection lasting 30 years or more after stopping 10
BRCA2 variant: about 17% by age 80 5Removing tubes and ovaries in BRCA carriers: about 80% lower ovarian and tubal cancer risk 12
Lynch syndrome and RAD51C, RAD51D or BRIP1 variantsPregnancy, and each further pregnancy
Endometriosis, mainly for clear cell and endometrioid typesBreastfeeding
Menopausal hormone therapy: about 1 extra case per 1,000 women taking it for 5 years from around 50 11Tubal ligation or removal of the tubes (salpingectomy)
Never being pregnant, obesity, and smoking (mucinous type)No supplement or diet has been shown to prevent ovarian cancer

Any link between PCOS and ovarian cancer is small and uncertain. If you are weighing hormone therapy around menopause, the ovarian figure is one line in a wider conversation about benefits and risks with your doctor.

Is there a blood test for ovarian cancer?

No blood test can find ovarian cancer or rule it out. The test doctors use is CA-125 (cancer antigen 125), a protein shed by cells lining the belly, chest and pelvis. A result of 35 U/mL or higher counts as raised, and NICE uses that cutoff to decide who gets a pelvic ultrasound 4. In the study that introduced the test, CA-125 was at or above 35 U/mL in about 8 in 10 women with ovarian cancer and in about 1% of healthy people 7. It is raised in only about half of stage I cancers 8. A normal CA-125 therefore cannot clear early cancer, and a raised one usually has another cause.

Example CA-125 result against the 35 U/mL cutoffU/mL

48 U/mLMildly raised
Below the cutoff0–35Raised: ultrasound next35–120
A CA-125 of 48 U/mL is above the 35 U/mL cutoff, which in NICE guidance means a pelvic ultrasound. Before menopause, a period, endometriosis or fibroids can explain a result in this range, but with symptoms the ultrasound is still the next step; after menopause the same number carries more weight. Your doctor reads it alongside your symptoms, your age and the scan.
Illustrative example value. The 35 U/mL cutoff and the ultrasound step come from NICE NG12 4.

If a raised CA-125 turned up on a routine or at-home panel and you have none of the symptoms above, the cause is usually something other than cancer. Note where you were in your cycle when the blood was drawn and book a routine appointment; your doctor will decide whether to repeat the test away from your period or go straight to an ultrasound. After menopause, an ultrasound is the usual next step. One reading matters less than the trend; see why trends beat single readings.

Why CA-125 can be raisedHow commonWhat usually sorts it out
A periodVery common before menopauseYour doctor may repeat it away from your period, but with symptoms the ultrasound still goes ahead; see blood tests on your period
Endometriosis or fibroidsCommonUltrasound, and the history of painful periods
PregnancyCommon in early pregnancyPregnancy test
Liver disease, heart failure, or fluid in the belly or chest from any causeLess commonLiver tests, heart tests, imaging
Ovarian, tubal or peritoneal cancerRareUltrasound, then CT or MRI, then tissue

Menopause changes what a raised CA-125 means. Before menopause, including perimenopause, periods, endometriosis and fibroids explain most raised results; after menopause those causes fade, so a raised CA-125 is more likely to matter. Once a mass is found, doctors may add HE4, a second protein that endometriosis raises less often than it raises CA-125, and combine the two with menopause status in a score called ROMA, or use a multi-marker test such as OVA1. These scores sort a known mass by how likely it is to be cancer; none of them is a screening test. Our guide to tumor markers covers how these markers work in general.

One blood test cannot clear every type. For a girl or young woman with an ovarian mass, doctors check the germ cell markers as well, because CA-125 often stays normal in these tumors. CEA and CA 19-9 come in when a tumor looks mucinous, to check whether it started in the ovary or spread from the bowel or appendix.

Can a routine blood test show ovarian cancer?

A complete blood count (CBC) or metabolic panel cannot find ovarian cancer, but some late clues are real. About 31% of women with epithelial ovarian cancer have a high platelet count at diagnosis 14. Low hemoglobin (anemia), low albumin and a raised CRP can also appear once the cancer is advanced. Each of these results has many more common causes, from iron deficiency to a recent infection, so they mean something only next to the symptom pattern.

Free, no accountRead your blood testHave a recent CBC or CA-125 result? Read what each line means.Read my results

Why there is no ovarian cancer screening test

Two large trials tested yearly CA-125 and transvaginal ultrasound (a scan through the vagina) in women without symptoms. In the US PLCO trial of about 78,000 women, screening did not lower ovarian cancer deaths; of 3,285 women with a false alarm, 1,080 had surgery, and 15% of those had at least one serious complication 9. The UK's UKCTOCS followed 202,638 women for a median of 16 years. Screening found more early-stage cancers but did not lower ovarian cancer deaths, and the authors wrote that the fall in stage III or IV disease "was not sufficient to translate into lives saved" 3.

The USPSTF recommends against screening for ovarian cancer in asymptomatic women.US Preventive Services Task Force, JAMA 2018 2

The task force gave screening a grade D, meaning the harms outweigh the benefits, for women without symptoms who are not known to carry a high-risk inherited variant 2. No trial has shown that multi-cancer blood tests or full-body MRI lower ovarian cancer deaths either; our page on the Galleri test covers what that test can find.

If you have symptoms: what your doctor will do

  1. 1Describe the patternName each symptom, how many days a month it happens, and when it started. Saying "bloating most days for six weeks" gets a faster response than "I feel bloated".
  2. 2ExaminationA belly and pelvic examination. NICE advises urgent referral straight away if the doctor finds fluid in the belly or a pelvic mass that is not obviously fibroids 4.
  3. 3CA-125 and a pelvic ultrasoundA CA-125 of 35 U/mL or more leads to an ultrasound of the belly and pelvis 4. If CA-125 is normal but symptoms persist, NICE advises looking for other causes and coming back if nothing explains them 4.
  4. 4Scoring and further imagingDoctors grade the ultrasound with standard checklists (IOTA or O-RADS) and may combine the findings with CA-125 and menopause status into a risk score (RMI, the risk of malignancy index, or ROMA). CT or MRI follows if the mass looks suspicious.
  5. 5A gynecologic oncologist and tissueOvarian cancer is diagnosed only on tissue from surgery or a biopsy. Surgery for a suspected ovarian cancer is best done by a gynecologic oncologist, a surgeon trained in these cancers, so ask who will operate.

Once ovarian cancer is confirmed, it is staged from I (inside the ovary or tube) to IV (spread to organs such as the lungs or liver) using FIGO, the international staging system for gynecologic cancers. Ovarian cancer survival rates depend mostly on stage, and US figures from SEER, the National Cancer Institute's cancer registry, use three broader stages 1.

Stage (SEER)What it meansShare of cases5-year relative survival
LocalizedConfined to the ovary or tube22%91.9%
RegionalSpread to nearby pelvic tissue or lymph nodes18%70.1%
DistantSpread through the belly lining or to distant organs54%31.5%
All stages100%52%

The survival figures come from women diagnosed between 2016 and 2022 1. Relative survival compares women with the cancer to women of the same age without it, so it leaves out deaths from other causes. An individual outlook also depends on the type of cancer, how much remains after surgery and how it responds to treatment. The three stage rows add up to 94% because about 6% of cases have no recorded stage.

BRCA, Lynch and family history: what to do before cancer

Genetic counseling is worth asking about if any of these apply to you:

  • A mother, sister, daughter or other close relative had ovarian cancer.
  • A relative carries a known BRCA or Lynch variant.
  • You have Ashkenazi Jewish ancestry.
  • A relative had breast cancer young, or several relatives had breast cancer.
  • Your family has many bowel or uterine cancers.

For carriers, the choice, made with a genetics team, is usually between removing the tubes and ovaries and watching with CA-125 and ultrasound, and the USPSTF screening advice does not cover them 2.

For BRCA carriers: surgery or watching

Removing tubes and ovariesLowers risk the most
Risk-reducing surgery
Effect on ovarian and tubal cancerAbout 80% lower risk
Usual timingOnce childbearing is finished, planned with a genetics team
Main trade-offImmediate menopause and the end of natural fertility
CA-125 and ultrasound checksA bridge, not protection
Surveillance
Effect on ovarian and tubal cancerNot shown to lower deaths; can miss early cancers
Usual timingFor carriers not yet ready for surgery
Main trade-offFalse alarms and extra tests
Surgery figure from Rebbeck, JNCI 2009 12.

About 18% of women with ovarian carcinoma carry an inherited variant 15, so ASCO, the American Society of Clinical Oncology, advises germline genetic testing (a blood or saliva test for gene changes you were born with) for every woman diagnosed with epithelial ovarian cancer 16. A positive result guides treatment and tells sisters and daughters that genetic testing is worth discussing with their own doctor or a genetic counselor.

Treatment, and how CA-125 is used afterward

Treatment is planned by a gynecologic oncology team and usually combines surgery to remove all visible cancer with platinum-based chemotherapy, given before surgery, after it, or both. Some women then take maintenance PARP inhibitors, tablets that stop cancer cells repairing their DNA; they help most when the tumor tests positive for a BRCA change or HRD (homologous recombination deficiency, a weakness in DNA repair) 16. Some early-stage cancers and most germ cell tumors can be treated with surgery that keeps the uterus and one ovary, so a later pregnancy is still possible.

After treatment, CA-125 is tracked in women whose level was raised at diagnosis. Read it as a trend, ideally from the same lab and the same test method, because different assays give different numbers. In the MRC OV05 trial, starting chemotherapy early on a rising CA-125 alone, before symptoms, did not help women live longer than waiting for symptoms or scan changes 17. A rising CA-125 after treatment prompts a scan and a conversation with the oncology team; the number alone does not set the next treatment.

Free, no accountDrop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.
Citations
  1. National Cancer Institute. SEER Cancer Stat Facts: Ovarian Cancer (accessed November 2026)
  2. US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319(6):588-594
  3. Menon U et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet 2021;397(10290):2182-2193
  4. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12)
  5. Kuchenbaecker KB et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402-2416
  6. Goff BA et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221-227
  7. Bast RC Jr et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309(15):883-887
  8. Charkhchi P et al. CA125 and ovarian cancer: a comprehensive review. Cancers 2020;12(12):3730
  9. Buys SS et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening randomized controlled trial. JAMA 2011;305(22):2295-2303
  10. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies. Lancet 2008;371(9609):303-314
  11. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385(9980):1835-1842
  12. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101(2):80-87
  13. American College of Obstetricians and Gynecologists. Committee Opinion No. 774: Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Obstet Gynecol 2019;133(4):e279-e284
  14. Stone RL et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366(7):610-618
  15. Norquist BM et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2(4):482-490
  16. Konstantinopoulos PA et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020;38(11):1222-1245
  17. Rustin GJS et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155-1163

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.